Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 6, 2026 | — | 87.67M | — | -0.17 | — |
| 2026 Q1 | May 7, 2026 | 71.43M | 77.84M | -0.19 | -0.19 | -13.20% |
| 2025 Q4 | February 24, 2026 | 86.71M | 80.71M | -0.18 | -0.22 | +30.80% |
| 2025 Q3 | November 6, 2025 | 67.46M | 82.17M | -0.25 | -0.29 | +27.62% |
| 2025 Q2 | August 7, 2025 | 59.95M | 78.32M | -0.33 | -0.29 | -20.08% |
| 2025 Q1 | May 8, 2025 | 49.32M | 82.37M | -0.36 | -0.25 | -44.79% |
| 2024 Q4 | February 27, 2025 | 73.69M | 72.17M | -0.26 | -0.27 | -19.49% |
| 2024 Q3 | November 7, 2024 | 58.55M | 71.57M | -0.28 | -0.31 | -13.80% |
| 2024 Q2 | August 8, 2024 | 31.11M | 24.59M | -0.34 | -0.37 | +24.94% |
| 2024 Q1 | May 9, 2024 | 715.00K | 2.07M | -0.42 | -0.45 | -18.48% |
| 2023 Q4 | February 28, 2024 | 482.00K | 1.39M | -0.45 | -0.44 | -8.72% |
| 2023 Q3 | November 7, 2023 | 469.00K | 1.72M | -0.46 | -0.46 | -3.47% |
| 2023 Q2 | August 8, 2023 | 238.00K | 3.58M | -0.47 | -0.81 | +6.44% |
| 2023 Q1 | May 9, 2023 | — | 200.00K | -0.50 | -0.84 | +3.80% |
| 2022 Q4 | February 28, 2023 | — | — | -0.64 | -0.64 | +0.14% |
| 2022 Q3 | November 3, 2022 | — | — | -0.63 | -0.64 | +4.34% |